

DAFTAR PUSTAKA

- Aberg, J.A., Lacy, C., Armstrong, L., Goldman, M., dan Lance, L.L., 2009. *Drug Information Handbook*, 17th ed. American Pharmacist Association.
- Achmad, A.F., Raharjani, Y.I., Setyaningrum, Z., Pramono, B.A., Selvyana, D.R., dan Negoro, S.P.W.B., 2022. Anticoagulant Therapy in Moderate to Severe COVID-19 Patients. *Mutiara Medika: Jurnal Kedokteran dan Kesehatan*, 22: 69–74.
- Aggarwal, M., Dass, J., dan Mahapatra, M., 2020. Hemostatic Abnormalities in COVID-19: An Update. *Indian Journal of Hematology and Blood Transfusion*, 36: 616–626.
- Ahmed, R., Ganguli, P., Singh, N., Singh, S., Gupta, U., Jaiswal, Y., dkk., 2019. Establishing reference ranges and normal values for coagulation screening in healthy Indian male volunteers enrolled for a longitudinal study. *Biomedical and Biotechnology Research Journal (BBRJ)*, 3: 22.
- Alam, M.R., Kabir, Md.R., dan Reza, S., 2021. Comorbidities might be a risk factor for the incidence of COVID-19: Evidence from a web-based survey. *Preventive Medicine Reports*, 21: 101319.
- Araya, S., Mamo, M.A., Tsegay, Y.G., Atlaw, A., Aytenew, A., Hordofa, A., dkk., 2021. Blood coagulation parameter abnormalities in hospitalized patients with confirmed COVID-19 in Ethiopia. *PLOS ONE*, 16: e0252939.
- Arifin, Z. dan Fatmawati, B.R., 2020. IDENTIFIKASI PASIEN COVID-19 BERDASARKAN RIWAYAT KONTAK 10: 6.
- Ashorobi, D., Ameer, M.A., dan Fernandez, R., 2021. *Thrombosis*, StatPearls [Internet]. StatPearls Publishing.
- ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P.R., Goligher, E.C., Berger, J.S., dkk., 2021a. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *The New England Journal of Medicine*, 385: 790–802.
- ATTACC Investigators, ACTIV-4a Investigators, REMAP-CAP Investigators, Lawler, P.R., Goligher, E.C., Berger, J.S., dkk., 2021b. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *The New England Journal of Medicine*, 385: 790–802.
- ATTACC Investigators, ACTIV-4a, dan The REMAP-CAP, 2021c. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *New England Journal of Medicine*, 385: 777–789.

- Aursulesei, V. dan Costache, I.I., 2019. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. *Clinical Cardiology*, 42: 774–782.
- Azizah, N.F., Faizah, R.N., Primasanti, D., Prihantini, I.K., dan Romadhian, I.G., 2022. Efektifitas Penggunaan Enoxaparin dan Fondaparinux Sebagai Antikoagulan Pada Pasien Covid-19 di RSUD Sidoarjo. *Majalah Farmaseutik*, 18: 57.
- Billett, H.H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L.R., Lo, Y., dkk., 2020. Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. *Thrombosis and Haemostasis*, 120: 1691–1699.
- Biswas, M., Rahaman, S., Biswas, T.K., Haque, Z., dan Ibrahim, B., 2021. Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirolgy*, 64: 36–47.
- Biswas, R., 2020. Are Men More Vulnerable to Covid-19 as Compared to Women? *Biomedical Journal of Scientific & Technical Research*, 27: .
- CDC, 2021. 'Coronavirus Disease 2019 (COVID-19) – Symptoms', *Centers for Disease Control and Prevention*. URL: <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html> (diakses tanggal 17/4/2021).
- Chaudhary, B., 2016. Thrombocytopenia and its causes 6.
- Costantino, G., Ceriani, E., Rusconi, A.M., Podda, G.M., Montano, N., Duca, P., dkk., 2012. Bleeding Risk during Treatment of Acute Thrombotic Events with Subcutaneous LMWH Compared to Intravenous Unfractionated Heparin; A Systematic Review. *PLoS ONE*, 7: e44553.
- Davidson, B.L., Verheijen, S., Lensing, A.W.A., Gebel, M., Brighton, T.A., Lyons, R.M., dkk., 2014. Bleeding Risk of Patients With Acute Venous Thromboembolism Taking Nonsteroidal Anti-Inflammatory Drugs or Aspirin. *JAMA Internal Medicine*, 174: 947.
- de Souza, F.S.H., Hojo-Souza, N.S., Batista, B.D. de O., da Silva, C.M., dan Guidoni, D.L., 2021. On the analysis of mortality risk factors for hospitalized COVID-19 patients: A data-driven study using the major Brazilian database. *PLOS ONE*, 16: e0248580.
- Di Gennaro, F., Pizzol, D., Marotta, C., Antunes, M., Racalbuto, V., Veronese, N., dkk., 2020. Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review. *International Journal of Environmental Research and Public Health*, 17: 2690.

- Duhri, A.P., Jabbar, R., dan Yunus, N., 2020. KARAKTERISTIK PASIEN KONFIRMASI COVID-19 DI RSUD LAMADDUKELLENG KABUPATEN WAJO (TINJAUAN PASIEN PERIODE MARET-SEPTEMBER 2020). *Media Kesehatan Politeknik Kesehatan Makassar*, 15: 319.
- Eljilany, I. dan Elzouki, A.-N., 2020. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review. *Vascular Health and Risk Management*, Volume 16: 455–462.
- Erlanda, W. dan Karani, Y., 2018. PENGGUNAAN ANTIKOAGULAN PADA PENYAKIT GINJAL KRONIK. *Jurnal Kesehatan Andalas*, 7: 168.
- Fattah, M.A., Shaheen, M.H., dan Mahfouz, M.H., 2004. Disturbances of Haemostasis in Diabetes Mellitus. *Disease Markers*, 19: 251–258.
- Fitriani, N.I., 2020. TINJAUAN PUSTAKA COVID-19: VIROLOGI, PATOGENESIS, DAN MANIFESTASI KLINIS 4: 8.
- Handayani, D., Hadi, D.R., Isbaniah, F., Burhan, E., dan Agustin, H., 2020. Penyakit Virus Corona 2019. *Jurnal Respirologi Indonesia*, 40: .
- Haqqani, O.P., Lafrati, M.D., dan Freedman, J.E., 2013. Chapter 7- Pharmacology of Antithrombotic Drugs 94–109.
- Harter, K., Levine, M., dan Henderson, S., 2015. Anticoagulation Drug Therapy: A Review. *Western Journal of Emergency Medicine*, 16: 11–17.
- Hazin, M.A.A., 2020. Anemia in chronic kidney disease. *Revista da Associação Médica Brasileira*, 66: s55–s58.
- Hirsh, J., Anand, S.S., Halperin, J.L., dan Fuster, V., 2001. Mechanism of Action and Pharmacology of Unfractionated Heparin. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 21: 1094–1096.
- Hosseinzadeh, R., Goharrizi, M.A.S.B., Bahardoust, M., Alvanegh, A.G., Ataei, M.R., Bagheri, M., dkk., 2021. Should all patients with hypertension be worried about developing severe coronavirus disease 2019 (COVID-19)? *Clinical Hypertension*, 27: 3.
- Hughes, S., Szeki, I., Nash, M.J., dan Thachil, J., 2014. Anticoagulation in chronic kidney disease patients--the practical aspects. *Clinical Kidney Journal*, 7: 442–449.
- Hunt, B.J., 2014. Bleeding and Coagulopathies in Critical Care. *New England Journal of Medicine*, 370: 847–859.

- IDI, 2020. *Rekomendasi IDI Pemberian Antikoagulan Profilaksis pada Pasien COVID-19 yang Dirawat di Rumah Sakit*. Jakarta.
- Jing, Z., Wei-jie, Y., Nan, Z., Yi, Z., dan Ling, W., 2012. Hemoglobin Targets for Chronic Kidney Disease Patients with Anemia: A Systematic Review and Meta-analysis. *PLoS ONE*, 7: e43655.
- Johnson, E.D., Schell, J.C., dan Rodgers, G.M., 2019. The D-dimer assay. *American Journal of Hematology*, 94: 833–839.
- Kaatz, S., Ahmad, D., Spyropoulos, A.C., Schulman, S., dan the Subcommittee on Control of Anticoagulation, 2015. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, 13: 2119–2126.
- Kattula, S., Byrnes, J.R., dan Wolberg, A.S., 2017. Fibrinogen and Fibrin in Hemostasis and Thrombosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 37: .
- Kee dan Hayes, 1996. *Farmakologi: Pendekatan Proses Keperawatan*. EGC, Jakarta.
- Khaerunnisa, R., Rumana, N.A., Yulia, N., dan Fannya, P., 2022. Gambaran Karakteristik Pasien Covid-19 di Rumah Sakit Mekar Sari Bekasi Tahun 2020-2021 10: 9.
- Khan, A., Althunayyan, S., Alsofayan, Y., Alotaibi, R., Mubarak, A., Arafat, M., dkk., 2020. Risk factors associated with worse outcomes in COVID-19: a retrospective study in Saudi Arabia. *Eastern Mediterranean Health Journal*, 26: 1371–1380.
- Klok, F.A., Kruip, M.J.H.A., van der Meer, N.J.M., Arbous, M.S., Gommers, D.A.M.P.J., Kant, K.M., dkk., 2020. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research*, 191: 145–147.
- Laouan Brem, F., Asmae, B., Amane, Y., Bouazzaoui, M.-A., Chaymae, M., Rasras, H., dkk., 2021. Diagnostic Accuracy of D-Dimers for Predicting Pulmonary Embolism in COVID-19-Patients. *Clinical and Applied Thrombosis/Hemostasis*, 27: 107602962110579.
- Law, J.P., Pickup, L., Townend, J.N., dan Ferro, C.J., 2020. Anticoagulant strategies for the patient with chronic kidney disease. *Clinical Medicine*, 20: 151–155.

- Lazrak, H.H., René, E., Elftouh, N., dan Lafrance, J.-P., 2018. Association Between Low-Molecular-Weight Heparin and Risk of Bleeding Among Hemodialysis Patients: A Retrospective Cohort Study. *Canadian Journal of Kidney Health and Disease*, 5: 205435811879201.
- Lee, M.W. dan Katz, P.O., 2021. Nonsteroidal Antiinflammatory Drugs, Anticoagulation, and Upper Gastrointestinal Bleeding. *Clinics in Geriatric Medicine*, 37: 31–42.
- Lemos, A.C.B., do Espírito Santo, D.A., Salvetti, M.C., Gilio, R.N., Agra, L.B., Pazin-Filho, A., dkk., 2020. Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). *Thrombosis Research*, 196: 359–366.
- Lestari, A.I., 2019. DIFFERENT AMOUNT OF THROMBOCYTES ON BLOOD STORAGE FOR 24 HOURS IN ROOM AND REFRIGERATOR. *Journal of Vocational Health Studies*, 3: 59.
- Li, B., Yang, J., Zhao, F., Zhi, L., Wang, X., Liu, L., dkk., 2020. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. *Clinical Research in Cardiology*, 109: 531–538.
- Li, X., Weber, N.C., Cohn, D.M., Hollmann, M.W., DeVries, J.H., Hermanides, J., dkk., 2021. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. *Journal of Clinical Medicine*, 10: 2419.
- Linkins, L.-A. dan Takach Lapner, S., 2017. Review of D-dimer testing: Good, Bad, and Ugly. *International Journal of Laboratory Hematology*, 39: 98–103.
- Lippi, G., Plebani, M., dan Henry, B.M., 2020. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. *Clinica Chimica Acta*, 506: 145–148.
- Liu, Z., Ji, S., Sheng, J., dan Wang, F., 2014. Pharmacological effects and clinical applications of ultra low molecular weight heparins 11.
- Long, H., Nie, L., Xiang, X., Li, H., Zhang, X., Fu, X., dkk., 2020. D-Dimer and Prothrombin Time Are the Significant Indicators of Severe COVID-19 and Poor Prognosis. *BioMed Research International*, 2020: 1–10.
- Maharianingsih, N.M., Sudirta, I.K., dan Suryaningsih, N.P.A., 2022. Karakteristik Pasien dan Penggunaan Obat Pada Pasien Covid-19 Derajat Sedang-Berat di RSUD Karangasem. *Indonesian Journal of Pharmaceutical Education*, 2: 86–94.
- Maryati, W., Agung Widyastuti, Agusta Pinta Kurnia Rizky, Puguh Ika Listyorini, dan Fhahrul Dwi Aryanti, 2022. Analisis Karakteristik Pada Pasien Rawat

Inap Kasus Covid-19. *Infokes: Jurnal Ilmiah Rekam Medis dan Informatika Kesehatan*, 12: 20–25.

- Merli, G., Spiro, T.E., Olsson, C.-G., Abildgaard, U., Davidson, B.L., Eldor, A., dkk., 2001. Subcutaneous Enoxaparin Once or Twice Daily Compared with Intravenous Unfractionated Heparin for Treatment of Venous Thromboembolic Disease 13.
- Norouzi, M., Norouzi, S., Ruggiero, A., Khan, M.S., Myers, S., Kavanagh, K., dkk., 2021. Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection. *Microorganisms*, 9: 1211.
- Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., dkk., 2021. Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. *Frontiers in Pharmacology*, 12: 670155.
- Oliynyk, O., Barg, W., Slifirczyk, A., Oliynyk, Y., Dubrov, S., Gurianov, V., dkk., 2021. Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy. *Life*, 11: 1032.
- Ouassou, H., Kharchoufa, L., Bouhrim, M., Daoudi, N.E., Imtara, H., Bencheikh, N., dkk., 2020. The Pathogenesis of Coronavirus Disease 2019 (COVID-19): Evaluation and Prevention. *Journal of Immunology Research*, 2020: 1–7.
- Pawlowski, C., Venkatakrishnan, A., Kirkup, C., Berner, G., Puranik, A., O'Horo, J.C., dkk., 2021. Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients. *EClinicalMedicine*, 33: 100774.
- PDPI, PERKI, PAPDI, PERDATIN, dan IDAI, 2020. *Pedoman Tatalaksana COVID-19 Edisi 3*, 3rd ed. Jakarta.
- Pinto, H.N., Fitriana, D.W., dan Mizarti, D., 2022. HIPERKOAGULOPATI PADA COVID-19. *Jurnal Human Care*, 7: 43–50.
- Poudel, A., Poudel, Y., Adhikari, A., Aryal, B.B., Dangel, D., Bajracharya, T., dkk., 2021. D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. *PLOS ONE*, 16: e0256744.
- Pratiwi, A.D.E. dan Adhityasmara, D., 2021. GAMBARAN PENGGUNAAN ANTIKOAGULAN PADA PASIEN COVID-19 DI SALAH SATU

RUMAH SAKIT RUJUKAN COVID-19 DI KOTA SEMARANG.
Sebatik, 25: 442–448.

- Putri, N.A., Putra, A.E., dan Mariko, R., 2021. Hubungan Usia, Jenis Kelamin Dan Gejala Dengan Kejadian COVID- 19 di Sumatera Barat. *Majalah Kedokteran Andalas*, 8.
- Ran, J., Song, Y., Zhuang, Z., Han, L., Zhao, S., Cao, P., dkk., 2020. Blood pressure control and adverse outcomes of COVID-19 infection in patients with concomitant hypertension in Wuhan, China. *Hypertension Research*, 43: 1267–1276.
- Satuan Tugas Penanganan COVID-19, W.R.P.C.-19, 2021. 'Peta Sebaran', *covid19.go.id*. URL: <https://covid19.go.id/peta-sebaran> (diakses tanggal 17/4/2021).
- Schol-Gelok, S., Galema-Boers, J. (Annette) M.H., van Gelder, T., Kruip, M.J.H.A., Roeters van Lennep, J.E., dan Versmissen, J., 2018. No effect of PCSK9 inhibitors on D-dimer and fibrinogen levels in patients with familial hypercholesterolemia. *Biomedicine & Pharmacotherapy*, 108: 1412–1414.
- Senewe, F.P., Pracoyo, N.E., Marina, R., dan Letelay, A.M., 2021. PENGARUH PENYAKIT PENYERTA/KOMORBID DAN KARAKTERISTIK INDIVIDU DENGAN KEJADIAN COVID-19 DI KOTA BOGOR TAHUN 2020 20: 11.
- Shinohara, M., Fujino, T., Yao, S., Yano, K., Akitsu, K., Koike, H., dkk., 2019. Assessment of the bleeding risk of anticoagulant treatment in non-severe frail octogenarians with atrial fibrillation. *Journal of Cardiology*, 73: 7–13.
- Singh, B., Mechineni, A., Kaur, P., Reid, R.-J., dan Maroules, M., 2021. COVID-19 and bleeding at unusual locations: Report of four cases. *Hematology, Transfusion and Cell Therapy*, 43: 214–218.
- Stoneham, S.M., Milne, K.M., Nuttall, E., Frew, G.H., Sturrock, B.R., Sivaloganathan, H., dkk., 2020. Thrombotic risk in COVID-19: a case series and case–control study. *Clinical Medicine*, 20: e76–e81.
- Surendra, H., Elyazar, I.R., Djaafara, B.A., Ekawati, L.L., Saraswati, K., Adrian, V., dkk., 2021. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. *The Lancet Regional Health - Western Pacific*, 9: 100108.
- Tabiban, S., Rahbar, K., Ghadrdoost, B., Zahed, N., Falaknazi, K., dan Piraste, H., 2017. Comparison of Enoxaparin Sodium and Standard Heparin for Hemodialysis Anticoagulation. *Nephro-Urology Monthly*, InPress: .

- Tadic, M., Saeed, S., Grassi, G., Taddei, S., Mancia, G., dan Cuspidi, C., 2021. Hypertension and COVID-19: Ongoing Controversies. *Frontiers in Cardiovascular Medicine*, 8: 639222.
- Tang, N., Bai, H., Chen, X., Gong, J., Li, D., dan Sun, Z., 2020a. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of Thrombosis and Haemostasis*, 18: 1094–1099.
- Tang, N., Bai, H., Chen, X., Gong, J., Li, D., dan Sun, Z., 2020b. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of Thrombosis and Haemostasis*, 18: 1094–1099.
- Thoreau, B., Galland, J., Delrue, M., Neuwirth, M., Stepanian, A., Chauvin, A., dkk., 2021. D-Dimer Level and Neutrophils Count as Predictive and Prognostic Factors of Pulmonary Embolism in Severe Non-ICU COVID-19 Patients. *Viruses*, 13: 758.
- Veeranki, S.P., Xiao, Z., Levorsen, A., Sinha, M., dan Shah, B.R., 2021. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients. *American Journal of Cardiovascular Drugs*, 21: 443–452.
- Venerito, M., Wex, T., dan Malfertheiner, P., 2010. Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies. *Pharmaceuticals*, 3: 2225–2237.
- WHO, 2020a. 'WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020', . URL: <https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020> (diakses tanggal 27/4/2021).
- WHO, 2020b. 'WHO Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020', . URL: <https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020> (diakses tanggal 17/4/2021).
- WHO, 2021. 'COVID-19 Weekly Epidemiological Update', . URL: <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/> (diakses tanggal 17/4/2021).
- Widjaja, J.T., Kwee, L., Giantara, A.K., Suabgiyo, H.A., Edwin, C., dan Putri, R.L., 2021. Karakteristik Pasien COVID-19 Rawat Inap di RS Immanuel Bandung, Indonesia. *Journal of Medicine and Health*, 3: .

- Willim, H.A., Hardigaloeh, A.T., dan Supit, A.I., 2020. Koagulopati pada Coronavirus Disease-2019 (COVID-19): Tinjauan pustaka. *Intisari Sains Medis*, 8.
- Wiwanitkit, V., 2011. Metformin high dosage and bleeding episode: A clinical case study. *Indian Journal of Endocrinology and Metabolism*, 15: 132.
- Wool, G.D. dan Miller, J.L., 2021. The Impact of COVID-19 Disease on Platelets and Coagulation. *Pathobiology*, 88: 15–27.
- Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, Xing, Xu, S., dkk., 2020. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Internal Medicine*, 180: 934.
- Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., dkk., 2020. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *International Journal of Infectious Diseases*, 94: 91–95.
- Yao, Y., Cao, J., Wang, Q., Shi, Q., Liu, K., Luo, Z., dkk., 2020. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. *Journal of Intensive Care*, 8: 49.
- Zhan, H., Chen, H., Liu, C., Cheng, L., Yan, S., Li, H., dkk., 2021. Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression. *Clinical and Applied Thrombosis/Hemostasis*, 27: 107602962110109.
- Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., dkk., 2020. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. *Journal of Infection*, 81: e16–e25.